US 12,433,941 B2
Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms
Stephen John Gould, Baltimore, MD (US); Linda Marban, Santa Monica, CA (US); and Tariq Hussain Warsi, Thousand Oaks, CA (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US); and Capricor, Inc., Beverly Hills, CA (US)
Appl. No. 17/909,610
Filed by The Johns Hopkins University, Baltimore, MD (US); and Capricor, Inc., Beverly Hills, CA (US)
PCT Filed Mar. 12, 2021, PCT No. PCT/US2021/022222
§ 371(c)(1), (2) Date Sep. 6, 2022,
PCT Pub. No. WO2021/183961, PCT Pub. Date Sep. 16, 2021.
Claims priority of provisional application 63/155,268, filed on Mar. 1, 2021.
Claims priority of provisional application 63/110,325, filed on Nov. 5, 2020.
Claims priority of provisional application 63/108,847, filed on Nov. 2, 2020.
Claims priority of provisional application 63/061,766, filed on Aug. 5, 2020.
Claims priority of provisional application 63/000,211, filed on Mar. 26, 2020.
Claims priority of provisional application 62/990,946, filed on Mar. 17, 2020.
Claims priority of provisional application 62/989,525, filed on Mar. 13, 2020.
Prior Publication US 2023/0142621 A1, May 11, 2023
Int. Cl. A61K 39/12 (2006.01); A61K 9/127 (2006.01); A61K 31/7105 (2006.01); A61K 35/28 (2015.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01); C07K 14/245 (2006.01); C12N 9/06 (2006.01); C12N 15/85 (2006.01); C12N 15/88 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 9/127 (2013.01); A61K 31/7105 (2013.01); A61K 35/28 (2013.01); A61P 31/14 (2018.01); C07K 14/245 (2013.01); C12N 9/003 (2013.01); C12N 15/85 (2013.01); C12N 15/88 (2013.01); A61K 2039/53 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01); C12N 2800/107 (2013.01); C12N 2830/002 (2013.01); C12N 2840/10 (2013.01)] 20 Claims
 
1. An extracellular vesicle (EV)-based nucleic acid composition, comprising one or more extracellular vesicles (EVs) each comprising a polynucleotide having an open reading frame (ORF) encoding a fusion protein comprising fragments of each of a plurality of antigenic peptides.